Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HGEN patent info (from Elisa on ST)
https://uspto.report/patent/grant/10899831
That was a disappointing Power Hour. But I guess it makes sense. A lot of investors bought around at $20 and have been waiting patiently for months. They saw the chance to take a 10% gain and took it.
I'm thinking we see a JP Morgan upgrade soon.
Is it weird how our stock goes idle after a 13d filing? Asking for a friend
Power Hour today
Tear The Roof Off The Sucker
For context: this is the guy I wrote about earlier this year who made a fortune on GameStop. He currently owns over a million shares of another heavily shorted stock, $hgen. And the payoff this time could be even bigger https://t.co/eDVNJ96odu
— David Hill (@davehill77) May 26, 2021
I still think more why not to use 700 mg for all doses ..
But I am trying to explain to myself that they know what they are doing ..:))
First dose 700 mg SC and then up to 3 more doses of 350 SC .
SC dose for moderate is ok imo , every hr here is not that important as with Critical patients ..
And so it begins.........
For example like herpes causing a blister and focusing on the blister and not the disease itself?
What about CYDY having to backpeddle down to "PNEUMONIA"?
So now CYDY trying to piggyback with other drugs to get approved? "Wonder drug" cant stand on its own to feet and go it alone?
https://www.nature.com/articles/d41586-021-01396-y
Lung samples from patients who had died showed monocytes and a further type of immune cell (macrophages) clustered in the lung’s tiny air sacs; this is associated with the damage that typifies severe COVID-19. The unusual receptors suggested to us that monocytes circulating in the blood had been both altered and summoned by the cytokines produced in the airway.
Ajinomoto expands fill-finish capacity
https://www.scienceboard.net/index.aspx?sec=ser&sub=def&pag=dis&ItemID=2746
I really don't know the reason , but something convinced them that lower dose but 2 weeks longer maybe better..
It seems Anthony Macuk of The Columbian is no longer pro-leronlimab. It is always weird when reporters from small newspapers write about leronlimab.
FDA says CytoDyn drug didn’t aid COVID cases
https://www.columbian.com/news/2021/may/25/fda-says-cytodyn-drug-didnt-aid-covid-cases/
Yea , I agree , this about the same type of patients lenzilumab is treating ,
I know 350 mg is less expensive , but this dose during the study makes me nervous.
When physicians treating patients later it is ok to try , but during study one cant change it ,
Well , we will see.
I will ask this question during next CC,,why ??
So shorts have previously shook out all of the weak hands with short attacks that dipped the share price into the 17s and 18s. Now they are trying to bore us to death at the $20 level. Is hitting $21 too much to ask? Meanwhile, institutions are loading up shares.
In critical , all IV 700 mg..'I am really surprised they will be using 350 in moderate , but they must observe something with LH study..
Still makes me nervous..
Sorry , I didnt see this new moderates patients protocol.
You were right that what they decided for the first time ,
first 700 mg SC then 3 SC 350 mg .
This makes me nervous , I must say.. but hopefully they have a reason for it.
Just to let you know.They never used 350 mg on COVID patients.ONLY 700 mg.
hopefully it becomes 1 IV and the rest subQ
So they are giving up to 4 doses once a week with all of them being 700mg intravenously instead of the first dose of 700mg intravenously and 3 doses of 350mg subcutaneously?
I wonder why all shorts are so happy with this new attack group.
Now is the perfect time for a regime change. Nothing is on the horizon. Brazil interim analysis is expected in Oct/Nov but it will almost surely come sometime in 2022.
It is hard to imagine the US FDA giving an EUA to CytoDyn while Nader is CEO. Whatever inefficiencies happen because of the regime change can't be worse than the inefficiencies that Nader causes on a daily basis through incompetence.
My guess is today's share price was intentionally bolstered by those initiating change. The share price will probably sink further over the next month. But getting rid of Nader is best for the long term interests of CytoDyn. Nader has fed into the delusion that revenue can be gained in poor countries. The only avenue to revenue is through the US FDA. Getting rid of Nader is CytoDyn's best chance at getting on the good side of government officials.
24% fewer people dying?
In my opinion, our lack of approval from the FDA has a lot more to do with the 11 out of 19 members of the Covid Task Force with financial ties to Gilead, than it does with Nader P.
I wonder which side Michael Mulholland is on? Timing of his exit is definitely interesting. He has always been the brains behind the operation. Bruce taking care of the science side and Mulholland taking care of the business side wouldn't be so bad.
Et tu, Bru-ce?
Thankfully the market's sort of yawning.
Agreed 100% the lenders love cydy it's been nothing but a piggy bank with a big pay out coming up when they finally get the lights shut off
Pizza Party Pat's newest
https://twitter.com/penetentiarypi1/status/1396903877799251968
Lenzilumab's status as game changer could have been predicted after the Imperial College London came out with their trial identifying GM-CSF as the cytokine responsible for the cytokine storm, severe Covid, and Covid death.
https://www.bbc.com/news/health-56352128
https://immunology.sciencemag.org/content/6/57/eabg9873
I keep coming back to the 296% efficacy on preventing mechanical ventilation for early and mid stage severe patients under 85yo. And 217% efficacy on mortality for the same group. No other treatment has shown even good results for severe patients. Lenzilumab is a game changer. Every patient under 85yo should receive lenzilumab as soon as they become hospitalized.
[Lenzilumab improved the likelihood of SWOV] by 2.96-fold in subjects with CRP<150 mg/L and age <85 years (2.96; 1.63–5.37, nominal p=0.0003); and by 88% in subjects hospitalized ≤2 days prior to randomization (1.88; 1.13-3.12, nominal p=0.015). Survival was improved by 2.17-fold in subjects with CRP<150 mg/L and age <85 years (2.17; 1.04-4.54, nominal p=0.040).
https://www.medrxiv.org/content/10.1101/2021.05.01.21256470v1.full-text
Well said Black-0PS, our own FDA changed the time frame so endpoints would fall short, Unbelievable...even more after seeing the interim results.
When way, way to much progress was made the FDA changed the time to 28 days.
Then 42 days.
Long Haulers getting well is not delusional.